Cancer immunotherapy drug 'less toxic and prolongs life' An immunotherapy drug that could save some cancer patients from the ordeal of extreme chemotherapy may also help them live longer, researchers say.
In a trial, pembrolizumab kept head and neck cancers at bay for an average of two years - five times longer than under chemotherapy.
The patients also suffered far fewer side-effects.
Cases of head and neck cancers are rising in the UK and most are diagnosed late, when they are harder to treat. BBC News
No comments:
Post a Comment